Sign Up | Log In | What is SocialPicks?

1 pt

Opinion on Valeant Pharmaceuticals International (VRX) Sector: Healthcare > Industry: Biotechnology & Drugs
Valeant's Promising Epilepsy Drug

Jun 03, 2009 06:53 PM GMT

jgarner3999

Return	Risk
+12.22%	LOW

Sr. Analyst

Profile & Performance

Subscribe to author

Valeant has a promising epilepsy drug, retigabine, that is significantly undervalued by Wall Street. Healey sees the stock doubling to $40 to $50 a share in the next 12 to 18 months - Joseph Healey, HEALTHCOR

VRX: This call was made on 06/03/09 @ $23.05

Rating:	$23.05 (06/03/09)
Closed:	07/30/2009 @ $25.19 (+9.28% in 57 days)
Target:	$35.00 (+51.84%) in > one year

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.37%	379
2	Gerald Greene	18.14	+70.70%	209
3	stockmarketfunding.com	17.66	+25.67%	55
4	akiralegrand	13.47	+14.32%	61
5	anup2104	12.13	+78.05%	39

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
XOM	Exxon Mobil Corp
FSLR	First Solar Inc.
MSFT	Microsoft Corp
PFE	Pfizer Inc
FRE	Freddie Mac
SIRI	Sirius Satellite Radio Inc

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

PARD		PARD - Azimuth Opportunity Bets on Poniard's Survival. Should you ? by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev
ABIO		BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO by Mike Havrilla
NVO		Diabetes Care: Global Investing Opportunities by Mike Havrilla

... more »

Valeant Pharmaceuticals International (VRX)

SocialPicks Sentiment:

This Quarter's Sentiment:

All:

66.5%

Top:

0.0%

Get Daily Email Alerts

Subscribe to jgarner3999

Receive Free Ideas Daily for This Sector

Latest Picks by jgarner3999

Symbol	Return	Since
TTWO	-1.36%	11/10/09
PL	-1.55%	11/10/09
LVS	-5.84%	11/10/09
F	+18.26%	09/04/09
TBT	-2.63%	08/27/09

View All >

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Opinion on Valeant Pharmaceuticals International (VRX) Sector: Healthcare > Industry: Biotechnology & Drugs Valeant's Promising Epilepsy Drug

Opinion on Valeant Pharmaceuticals International (VRX) Sector: Healthcare > Industry: Biotechnology & Drugs
Valeant's Promising Epilepsy Drug